Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04262856
Title	Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
Acronym	ARC-7
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Arcus Biosciences, Inc.
Indications	lung non-squamous non-small cell carcinoma lung squamous cell carcinoma
Therapies	AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab
Age Groups:	senior \| adult
Covered Countries	USA \| CAN \| AUS